Aligos Therapeutics Statistics
Total Valuation
ALGS has a market cap or net worth of $10.56 million. The enterprise value is -$8.63 million.
| Market Cap | 10.56M |
| Enterprise Value | -8.63M |
Important Dates
The last earnings date was Friday, November 6, 2026, before market open.
| Earnings Date | Nov 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ALGS has 6.25 million shares outstanding. The number of shares has increased by 17.65% in one year.
| Current Share Class | 5.45M |
| Shares Outstanding | 6.25M |
| Shares Change (YoY) | +17.65% |
| Shares Change (QoQ) | +0.30% |
| Owned by Insiders (%) | 2.22% |
| Owned by Institutions (%) | 18.29% |
| Float | 3.36M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.31 |
| Forward PS | 4.19 |
| PB Ratio | 1.16 |
| P/TBV Ratio | 0.93 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.77, with a Debt / Equity ratio of 1.05.
| Current Ratio | 1.77 |
| Quick Ratio | 1.59 |
| Debt / Equity | 1.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -159.46% and return on invested capital (ROIC) is -89.66%.
| Return on Equity (ROE) | -159.46% |
| Return on Assets (ROA) | -57.76% |
| Return on Invested Capital (ROIC) | -89.66% |
| Return on Capital Employed (ROCE) | -262.87% |
| Weighted Average Cost of Capital (WACC) | 8.25% |
| Revenue Per Employee | $410,317 |
| Profits Per Employee | -$808,354 |
| Employee Count | 82 |
| Asset Turnover | 0.43 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, ALGS has paid $3.48 million in taxes.
| Income Tax | 3.48M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -73.72% in the last 52 weeks. The beta is 2.43, so ALGS's price volatility has been higher than the market average.
| Beta (5Y) | 2.43 |
| 52-Week Price Change | -73.72% |
| 50-Day Moving Average | 4.85 |
| 200-Day Moving Average | 5.98 |
| Relative Strength Index (RSI) | 18.80 |
| Average Volume (20 Days) | 65,120 |
Short Selling Information
The latest short interest is 677,218, so 10.84% of the outstanding shares have been sold short.
| Short Interest | 677,218 |
| Short Previous Month | 707,471 |
| Short % of Shares Out | 10.84% |
| Short % of Float | 20.15% |
| Short Ratio (days to cover) | 17.16 |
Income Statement
In the last 12 months, ALGS had revenue of $33.65 million and -$66.29 million in losses. Loss per share was -$6.37.
| Revenue | 33.65M |
| Gross Profit | -49.69M |
| Operating Income | -72.52M |
| Pretax Income | -62.80M |
| Net Income | -66.29M |
| EBITDA | -71.41M |
| EBIT | -72.52M |
| Loss Per Share | -$6.37 |
Balance Sheet
The company has $31.09 million in cash and $11.90 million in debt, with a net cash position of $19.19 million or $3.07 per share.
| Cash & Cash Equivalents | 31.09M |
| Total Debt | 11.90M |
| Net Cash | 19.19M |
| Net Cash Per Share | $3.07 |
| Equity (Book Value) | 11.31M |
| Book Value Per Share | 1.81 |
| Working Capital | 15.08M |
Cash Flow
In the last 12 months, operating cash flow was -$68.37 million and capital expenditures -$289,000, giving a free cash flow of -$68.66 million.
| Operating Cash Flow | -68.37M |
| Capital Expenditures | -289,000 |
| Depreciation & Amortization | 1.11M |
| Net Borrowing | -89,000 |
| Free Cash Flow | -68.66M |
| FCF Per Share | -$10.99 |
Margins
Gross margin is -147.67%, with operating and profit margins of -215.55% and -197.01%.
| Gross Margin | -147.67% |
| Operating Margin | -215.55% |
| Pretax Margin | -186.65% |
| Profit Margin | -197.01% |
| EBITDA Margin | -212.25% |
| EBIT Margin | -215.55% |
| FCF Margin | n/a |
Dividends & Yields
ALGS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -17.65% |
| Shareholder Yield | -17.65% |
| Earnings Yield | -376.82% |
| FCF Yield | -654.07% |
Analyst Forecast
The average price target for ALGS is $36.88, which is 2,082.25% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $36.88 |
| Price Target Difference | 2,082.25% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 34.78% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on August 19, 2024. It was a reverse split with a ratio of 1:25.
| Last Split Date | Aug 19, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
ALGS has an Altman Z-Score of -23.66 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -23.66 |
| Piotroski F-Score | 2 |